HPVTIMER: A shiny web application for tumor immune estimation in human papillomavirus‐associated cancers
iMeta · 2023-08 · 2 (3)
DOI: 10.1002/imt2.130 ↗Kurz gefasst
Fachartikel in der Zeitschrift iMeta, online erschienen am 12.08.2023. Verfasst von Liying Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology Zhujiang Hospital, Southern Medical University Guangzhou Guangdong China. Die Arbeit wurde bisher 62-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Planning Project of Guangdong Province, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
The tumor immune microenvironment (TIME) is closely associated with tumor formation, particularly linked to the human papillomavirus (HPV), and regulates tumor initiation, proliferation, infiltration, and metastasis. With the rise of immunotherapy, an increasing amount of sample data used for TIME exploration is available in databases. However, no currently available web tool enables a comprehensive exploration of the TIME of HPV‐associated cancers by leveraging these data. We have developed a web tool called HPV‐associated Tumor Immune MicroEnvironment ExploreR (HPVTIMER), which provides a comprehensive analysis platform that integrates over 10,000 genes and 2290 tumor samples from 65 transcriptome data sets across 8 cancer types sourced from the Gene Expression Omnibus (GEO) database. The tool features four built‐in analysis modules, namely, the differential expression analysis module, correlation analysis module, immune infiltration analysis module, and pathway analysis module. These modules enable users to perform systematic and vertical analyses. We used several analytical modules in HPVTIMER to briefly explore the role of CDKN2A in head and neck squamous cell carcinomas. We expect that HPVTIMER will help users explore the immune microenvironment of HPV‐associated cancers and uncover potential immune regulatory mechanisms and immunotherapeutic targets. HPVTIMER is available at http://www.hpvtimer.com/ .
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology Zhujiang Hospital, Southern Medical University Guangzhou Guangdong China.
- The First Clinical Medical School Southern Medical University Guangzhou Guangdong China.
- The Second Clinical Medicine School Southern Medical University Guangzhou Guangdong China.
- Department of Surgical Oncology Sir Run Run Shaw Hospital Affiliated to Zhejiang University, School of Medicine Hang Zhou China.
- Thoracic Surgery Branch Center for Cancer Research, National Institutes of Health Bethesda Maryland USA.
- Department of Pathogenic Microbiology and Immunology Xi'an Jiaotong University Xi'an Shaanxi China.
ORCID-Profile: Liying Liu, Yanan Xie, Hong Yang, Anqi Lin, Haitao Wang, Cangang Zhang, Zaoqu Liu, Quan Cheng, Peng Luo
Förderung
- National Natural Science Foundation of China
- Science and Technology Planning Project of Guangdong Province
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Liu, L., Xie, Y., Yang, H., Lin, A., Dong, M., Wang, H., Zhang, C., Liu, Z., Cheng, Q., Zhang, J., Yuan, S., & Luo, P. (2023). HPVTIMER: A shiny web application for tumor immune estimation in human papillomavirus‐associated cancers. iMeta, 2(3). https://doi.org/10.1002/imt2.130
Vancouver
Liu L, Xie Y, Yang H, Lin A, Dong M, Wang H, et al. HPVTIMER: A shiny web application for tumor immune estimation in human papillomavirus‐associated cancers. iMeta. 2023;2(3). doi:10.1002/imt2.130
BibTeX
@article{Liu2023,
author = {Liu, Liying and Xie, Yanan and Yang, Hong and Lin, Anqi and Dong, Minjun and Wang, Haitao and Zhang, Cangang and Liu, Zaoqu and Cheng, Quan and Zhang, Jian and Yuan, Shuofeng and Luo, Peng},
title = {HPVTIMER: A shiny web application for tumor immune estimation in human papillomavirus‐associated cancers},
journal = {iMeta},
year = {2023},
volume = {2},
number = {3},
doi = {10.1002/imt2.130}
}
EUVIMED